OWINGS MILLS, Md., Jan. 3, 2017 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven weight-loss and healthy living products and programs, announced today that Daniel R. Chard, Chief Executive Officer, and Timothy Robinson, Chief Financial Officer, will present at the 19th Annual ICR Conference on Tuesday, January 10, 2017 in Orlando, FL.
The presentation is scheduled to begin at 12:00 p.m. ET. The presentation will be broadcast live over the Internet hosted at the Investor Relations section of Medifast's website at www.MedifastNow.com, and will be archived online through Tuesday, January 24, 2017.
Medifast (NYSE: MED) is the leading easy-to-use provider of clinically proven weight-loss and healthy living products and programs. Medifast aims to help customers lead a healthier lifestyle through a holistic approach to weight-loss and weight management, nutrition education and fitness. Medifast's proven results are based on the use of structured meal plans featuring Medifast Meals, which are nutritionally designed to assist customers with successful weight-loss and weight management. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto www.MedifastNow.com.
SOURCE Medifast, Inc.
For further information: Investors - ICR, Inc., Katie Turner, (646) 277-1228
Medifast makes no claim that these results are representative of all participants on the Medifast Program. Medifast recommends you consult with a physician before starting a weight-loss program. Individual results will vary. Medifast is the brand recommended by more than 20,000 doctors since 1980. Typical weight loss on the Medifast 5 & 1 Plan® is 2-5 lbs per week for the first two weeks and 1-2 lbs per week thereafter.